Professor Gary Levy is Professor of the Departments of Medicine, Immunology  and Surgery at the University of Toronto, Canada.  He served as the Director of the Multi Organ Transplant Program at the University Health Network  and Director of the University of Toronto Transplant Institute until June 30, 2013. Prof. Levy graduated from medical school at the University of Toronto in 1973, and undertook postdoctoral training in immunology at the Scripps Clinic and Research Foundation. In 1988, he was elected to be a member of the American Society for Clinical Investigation, and later organized and co-founded the Multi Organ Transplant Program at the University Health Network and the University of Toronto Transplantation Institute. Prof. Levy has received numerous awards and lectureships throughout his career, including the William Goldie Price in Medicine, the Canadian Liver Foundation Commemorative Medal for the Queen’s Jubilee for his outstanding contribution to the study of liver disease, the Ivan T. Beck Lectureship from the Canadian Association of Gastroenterology, the Dr Richard Hunt Outstanding Service Award from the Canadian Digestive Health Foundation and the Williams Calne Lectureship from the British Association for the Study of the Liver. He is an Honorary Professor at Tongji University, Wuhan China. Prof. Levy is also a member of many national and international medical societies and committees, and was elected as  a Fellow of the American Gastroenterological Association,  the Canadian Association of Gastroenterology the American Association for Studies of Liver Disease and in 2015 was appointed to the Order of Ontario. He serves on the editorial boards of numerous journals including Transplantation, Liver Transplantation and the Journal of Immunology. He serves on the executive committee of the Institute of Medical Sciences, University of Toronto and is Medical Director  and Head of the Scientific Advisory Board of Therapure Pharma Inc. Prof. Levy’s research has focused on the immune-mediated mechanisms of organ injury due to viruses, alloantigens and xenoantigens. His  research and clinical focus presently is  on finding a way to achieve immunological tolerance, which could allow patients who have undergone solid organ transplant to discontinue their long term need for immunosuppression. He has published over 400 peer-reviewed articles, books and book chapters, and has trained over 60 masters and PhD students.
Skip to toolbar